Cargando…
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
SIMPLE SUMMARY: Colorectal cancer with a mutation in an oncogene BRAF has paid much attention, as it comprises a population with dismal prognosis since two decades ago. A series of research since then has successfully changed this malignancy to be treatable with specific treatment. Here we thoroughl...
Autores principales: | Nakayama, Izuma, Hirota, Toru, Shinozaki, Eiji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694028/ https://www.ncbi.nlm.nih.gov/pubmed/33152998 http://dx.doi.org/10.3390/cancers12113236 |
Ejemplares similares
-
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017) -
BRAF Mutation in Colorectal Cancer: An Update
por: Barras, David
Publicado: (2015) -
BRAF Mutated Colorectal Cancer: New Treatment Approaches
por: Molina-Cerrillo, Javier, et al.
Publicado: (2020) -
BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
por: Caputo, Francesco, et al.
Publicado: (2019) -
BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies
por: Wang, Pei-Pei, et al.
Publicado: (2022)